Market Overview:
The global aurora kinase c market is expected to grow at a CAGR of XX% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing incidence of cancer, rising demand for targeted therapies, and technological advancements in the field of cancer treatment. The global aurora kinase c market is segmented on the basis of type, application, and region. On the basis of type, it is divided into AMG-900, danusertib (AZD1152), ilarasertib (MLN8237), NMI-900 (BMS-754807), SAR-156497 (AZD5363), and others. On the basis of application, it is classified into solid tumor cancers such as colorectal cancer and pancreatic cancer; non-small cell lung cancers such as adenocarcinoma and squamous cell carcinoma; acute lymphocytic leukemia; myelodysplastic syndrome; chronic myeloid leukemia; other blood cancers including multiple myeloma and Hodgkin’s lymphoma; ovarian cancer; prostate cancer; breast cancer ;and others. Geographically, it is analyzed across North America including Canada & Mexico , Latin America including Brazil & Argentina , Europe including Germany France Italy Spain United Kingdom ), Asia Pacific excluding Japan( China India South Korea Australia New Zealand )and Middle East Africa .
Product Definition:
Aurora Kinase C (AURKC) is a protein that in humans is encoded by the AURKC gene. Aurora kinases are serine/threonine kinases that play important roles in mitosis. Aurora C has been shown to be essential for cytokinesis, the final step of mitosis.
AMG-900:
AMG-900 is a Kinase inhibitor developed by Aurora Biomed. It was initially designed for the treatment of cancer, however it has been found to have an effect on the kinases associated with multiple sclerosis and Alzheimer’s disease. AMG-900 has shown promising results in phase II clinical trials as a potential treatment for patients suffering from advanced stages of multiple sclerosis and/or relapsing forms of MS.
Danusertib:
Danusertib (INN) is a novel oral inhibitor of BCR-ABL1, developed by Incyte Pharmaceuticals Inc. and is currently in phase II clinical trials for the treatment of chronic myeloid leukemia. Danusertib has shown potent anti-leukemia activity in vitro and in vivo as compared to other existing therapies.
Application Insights:
The acute lymphocytic leukemia segment held the largest share of 16.2% in 2017. The segment is anticipated to witness significant growth during the forecast period, owing to its high unmet medical need and availability of few approved therapies for the treatment of this condition. Acute lymphocytic leukemia (ALL) comprises two main types, namely primary and secondary leukemias. Primary ALL is a rare disease with only several hundred cases reported annually worldwide while secondary leukemias are relatively more common with over 10,000 new cases reported every year in 2014 globally according to data published by NCBI.
Rising prevalence of cancer across various regions coupled with limited treatment options available for many types is expected to boost market growth during the forecast period (2018-2030).
Regional Analysis:
North America dominated the global arena kinase C market in 2017. This can be attributed to the presence of a large number of key players, high R&D investment by companies and universities, and availability of effective treatment methods for various cancers. The region is expected to maintain its dominance during the forecast period as well owing to continuous developments undertaken by major companies for commercializing novel drugs at a relatively lower price.
Asia Pacific is anticipated to witness lucrative growth over the forecast period owing to increasing awareness about cancer among people coupled with government initiatives such as “One Belt One Road†(OBOR) program initiated by China government which aims at developing trade activities across Asia Pacific countries including China and India thus creating new avenues for pharmaceutical products including drugs.
Growth Factors:
- Increasing incidence of cancer: The increasing incidence of cancer is the major growth driver for the Aurora Kinase C market. According to the American Cancer Society, around 1,685,210 new cases of cancer will be diagnosed in the U.S. in 2017 and about 600,920 people will die from this disease. This number is expected to rise in future due to increase in aging population and lifestyle changes.
- Rising demand for targeted therapies: The growing demand for targeted therapies is another key growth driver for the Aurora Kinase C market as these therapies are more effective than traditional chemotherapy regimens and have fewer side effects. For instance, Roche’s Herceptin (trastuzumab) targets HER2-positive tumors and has been approved by FDA for treatment of breast cancer patients who have not responded to other treatments or those with metastatic disease.
Scope Of The Report
Report Attributes
Report Details
Report Title
Aurora Kinase C Market Research Report
By Type
AMG-900, Danusertib, Ilorasertib, NMI-900, SAR-156497, Others
By Application
Solid Tumor, Non-Small Cell Lung Cancer, Acute Lymphocytic Leukemia, Others
By Companies
AbbVie Inc, Amgen Inc, Cielo Therapeutics Inc, Sanofi, AbbVie Inc
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
139
Number of Tables & Figures
98
Customization Available
Yes, the report can be customized as per your need.
Global Aurora Kinase C Market Report Segments:
The global Aurora Kinase C market is segmented on the basis of:
Types
AMG-900, Danusertib, Ilorasertib, NMI-900, SAR-156497, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Solid Tumor, Non-Small Cell Lung Cancer, Acute Lymphocytic Leukemia, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- AbbVie Inc
- Amgen Inc
- Cielo Therapeutics Inc
- Sanofi
- AbbVie Inc
Highlights of The Aurora Kinase C Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- AMG-900
- Danusertib
- Ilorasertib
- NMI-900
- SAR-156497
- Others
- By Application:
- Solid Tumor
- Non-Small Cell Lung Cancer
- Acute Lymphocytic Leukemia
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Aurora Kinase C Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Aurora kinase C is a protein that in humans is encoded by the AKC gene. Aurora kinases are enzymes that catalyze the transfer of phosphate groups from ATP to other molecules, including proteins. This activity has been implicated in a variety of cellular processes, including cell growth and proliferation, signal transduction, and transcriptional regulation.
Some of the key players operating in the aurora kinase c market are AbbVie Inc, Amgen Inc, Cielo Therapeutics Inc, Sanofi, AbbVie Inc.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Aurora Kinase C Market Overview 4.1 Introduction 4.1.1 Market Taxonomy 4.1.2 Market Definition 4.1.3 Macro-Economic Factors Impacting the Market Growth 4.2 Aurora Kinase C Market Dynamics 4.2.1 Market Drivers 4.2.2 Market Restraints 4.2.3 Market Opportunity 4.3 Aurora Kinase C Market - Supply Chain Analysis 4.3.1 List of Key Suppliers 4.3.2 List of Key Distributors 4.3.3 List of Key Consumers 4.4 Key Forces Shaping the Aurora Kinase C Market 4.4.1 Bargaining Power of Suppliers 4.4.2 Bargaining Power of Buyers 4.4.3 Threat of Substitution 4.4.4 Threat of New Entrants 4.4.5 Competitive Rivalry 4.5 Global Aurora Kinase C Market Size & Forecast, 2020-2028 4.5.1 Aurora Kinase C Market Size and Y-o-Y Growth 4.5.2 Aurora Kinase C Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 AMG-900
5.2.2 Danusertib
5.2.3 Ilorasertib
5.2.4 NMI-900
5.2.5 SAR-156497
5.2.6 Others
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Solid Tumor
6.2.2 Non-Small Cell Lung Cancer
6.2.3 Acute Lymphocytic Leukemia
6.2.4 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Aurora Kinase C Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Aurora Kinase C Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 AMG-900
9.6.2 Danusertib
9.6.3 Ilorasertib
9.6.4 NMI-900
9.6.5 SAR-156497
9.6.6 Others
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Solid Tumor
9.10.2 Non-Small Cell Lung Cancer
9.10.3 Acute Lymphocytic Leukemia
9.10.4 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 AMG-900
10.6.2 Danusertib
10.6.3 Ilorasertib
10.6.4 NMI-900
10.6.5 SAR-156497
10.6.6 Others
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Solid Tumor
10.10.2 Non-Small Cell Lung Cancer
10.10.3 Acute Lymphocytic Leukemia
10.10.4 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 AMG-900
11.6.2 Danusertib
11.6.3 Ilorasertib
11.6.4 NMI-900
11.6.5 SAR-156497
11.6.6 Others
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Solid Tumor
11.10.2 Non-Small Cell Lung Cancer
11.10.3 Acute Lymphocytic Leukemia
11.10.4 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 AMG-900
12.6.2 Danusertib
12.6.3 Ilorasertib
12.6.4 NMI-900
12.6.5 SAR-156497
12.6.6 Others
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Solid Tumor
12.10.2 Non-Small Cell Lung Cancer
12.10.3 Acute Lymphocytic Leukemia
12.10.4 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 AMG-900
13.6.2 Danusertib
13.6.3 Ilorasertib
13.6.4 NMI-900
13.6.5 SAR-156497
13.6.6 Others
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Solid Tumor
13.10.2 Non-Small Cell Lung Cancer
13.10.3 Acute Lymphocytic Leukemia
13.10.4 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Aurora Kinase C Market: Competitive Dashboard
14.2 Global Aurora Kinase C Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 AbbVie Inc
14.3.2 Amgen Inc
14.3.3 Cielo Therapeutics Inc
14.3.4 Sanofi
14.3.5 AbbVie Inc